Conference Call with Hester Biosciences Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY23 & FY23 results: Standalone Q4FY23 & FY23: Overall gross profit margin reduced by 1% due to the change in product mix between vaccines and health products, health products sales having gone up. Operating EBITDA increased with the increase in sales. The reduction in EBITDA margin was due to the reduction in Gross Profit margin, accompanied by higher market development costs in animal health division and the new pet division Q4 PAT margin benefited from lower finance costs due to the reversal of unrealized forex loss of Rs 6.46 million on the translation of USD loan in Q4FY23, as against a loss of Rs 5.31 million in Q4FY22. Consequently, PAT increased by 27% from Rs 49.48 million to Rs 62.63 million. Result PDF